All In Biotech

Drug Trial Radar · NCT07909655

A Phase 2 Study of HB0056 in Patients With Idiopathic Pulmonary Fibrosis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Treatment of Idiopathic Pulmonary Fibrosis Patients With HB0056

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jan 2028

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a 58 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of HB0056, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF.

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)

Interventions

  • HB0056Drug

    subjects be given HB0056 high dose

  • HB0056Drug

    subjects be given HB0056 low dose

  • PlaceboDrug

    subjects be given placebo during the first 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in FVC% (Percent of Predicted FVC value) to week 24Time frame: 24 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fudan University Affiliated Zhongshan Hospital

    Shanghai, China

  • Xiangya Third Hospital of Central South University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.